NeOnc Technologies announced that CEO Amir Heshmatpour purchased 80,000 shares of common stock in the open market, bringing his total 2026 personal investment to 271,000 shares. Additionally, the company received a Type B End-of-Phase meeting from the FDA scheduled for January 2027 to discuss an accelerated approval pathway for its brain cancer candidate, NEO100.
NeOnc Technologies announced it will present data from its NEO100 and NEO212 clinical programs at the 31st Annual Meeting of the Society for Neuro-Oncology in November 2026. The presentations will cover Phase 1/2a results for intranasal NEO100 in astrocytoma and Phase 1 safety and PK data for oral NEO212 in recurrent GBM. This filing serves as an announcement of the upcoming presentations and does not disclose the specific clinical results or data points.
NeOnc Technologies has scheduled an in-person End-of-Phase 1 Type B meeting with the FDA for November 17, 2026, to discuss the clinical development of NEO212. The company intends to seek feedback on Phase 2 study design, patient populations, and potential accelerated approval pathways following encouraging Phase 1 results in glioblastoma and brain metastases.